S&P 500
$5,911.16
+1.9%
+$108.34
DJI
$42,253.52
+1.6%
+$650.45
NASDAQ
$19,167.75
+2.3%
+$430.54
Bitcoin
110,384.00
+0.8%
+872.52
AAPL
$199.98
+2.4%
+$4.71
AMZN
$206.10
+2.5%
+$5.11
GOOG
$173.43
+2.3%
+$3.84
META
$641.12
+2.2%
+$14.06
MSFT
$458.61
+1.9%
+$8.43
NVDA
$135.26
+3.0%
+$3.98
TSLA
$360.70
+6.3%
+$21.36
Arch Therapeutics (OTC: ARTH)
$0.00
Price as of May 20, 2025, 2:45 p.m. ET
Arch Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Arch Therapeutics Company Info
Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.
News & Analysis
No articles found.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.